These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23662044)
21. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy. Anandharaj A; Cinghu S; Park WY Acta Biochim Biophys Sin (Shanghai); 2011 Apr; 43(4):292-300. PubMed ID: 21367753 [TBL] [Abstract][Full Text] [Related]
22. Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition. Nam HY; Han MW; Chang HW; Lee YS; Lee M; Lee HJ; Lee BW; Lee HJ; Lee KE; Jung MK; Jeon H; Choi SH; Park NH; Kim SY; Kim SW Cancer Res; 2013 Jul; 73(14):4267-77. PubMed ID: 23722550 [TBL] [Abstract][Full Text] [Related]
23. [Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells]. Zhou LH; Zhu XP; Xiao HF; Xin PL; Li CT Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1397-1405. PubMed ID: 29070114 [TBL] [Abstract][Full Text] [Related]
24. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Wang WJ; Long LM; Yang N; Zhang QQ; Ji WJ; Zhao JH; Qin ZH; Wang Z; Chen G; Liang ZQ Acta Pharmacol Sin; 2013 May; 34(5):681-90. PubMed ID: 23603977 [TBL] [Abstract][Full Text] [Related]
25. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751 [TBL] [Abstract][Full Text] [Related]
26. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Wei F; Liu Y; Guo Y; Xiang A; Wang G; Xue X; Lu Z Mol Cancer; 2013 Jul; 12():81. PubMed ID: 23886294 [TBL] [Abstract][Full Text] [Related]
27. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225 [TBL] [Abstract][Full Text] [Related]
28. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Hui IC; Tung EK; Sze KM; Ching YP; Ng IO Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851 [TBL] [Abstract][Full Text] [Related]
29. Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation. Qiao Q; Jiang Y; Li G Oncol Rep; 2013 Jan; 29(1):380-6. PubMed ID: 23117293 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of mTOR enhances radiosensitivity of lung cancer cells and protects normal lung cells against radiation. Zheng H; Wang M; Wu J; Wang ZM; Nan HJ; Sun H Biochem Cell Biol; 2016 Jun; 94(3):213-20. PubMed ID: 26999331 [TBL] [Abstract][Full Text] [Related]
31. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441 [TBL] [Abstract][Full Text] [Related]
32. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia. Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465 [TBL] [Abstract][Full Text] [Related]
33. Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells. Horie R; Nakamura O; Yamagami Y; Mori M; Nishimura H; Fukuoka N; Yamamoto T Int J Oncol; 2016 Jan; 48(1):37-44. PubMed ID: 26530936 [TBL] [Abstract][Full Text] [Related]
34. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Chang Q; Chen E; Hedley DW Cancer Biol Ther; 2009 Oct; 8(20):1893-901. PubMed ID: 20009539 [TBL] [Abstract][Full Text] [Related]
35. [Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice]. Wang Z; Fan J; Zhou J; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1666-70. PubMed ID: 16854316 [TBL] [Abstract][Full Text] [Related]
36. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Kuger S; Flentje M; Djuzenova CS Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922 [TBL] [Abstract][Full Text] [Related]
37. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1. Wang YD; Su YJ; Li JY; Yao XC; Liang GJ Int J Clin Exp Pathol; 2015; 8(5):5182-8. PubMed ID: 26191215 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt. Lai Y; Yu X; Lin X; He S Int J Mol Med; 2016 Feb; 37(2):369-77. PubMed ID: 26707081 [TBL] [Abstract][Full Text] [Related]
39. Rapamycin inhibits tumor growth of human osteosarcomas. Zhao S; Lu N; Chai Y; Yu X J BUON; 2015; 20(2):588-94. PubMed ID: 26011354 [TBL] [Abstract][Full Text] [Related]
40. mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Utomo WK; Narayanan V; Biermann K; van Eijck CH; Bruno MJ; Peppelenbosch MP; Braat H Cancer Lett; 2014 May; 346(2):309-17. PubMed ID: 24467966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]